The Jordanian Pharmaceutical Manufacturing Company - Public Shareholding Company (ASE:JPHM)
Jordan · Delayed Price · Currency is JOD 1.490
0.00 (0.00%)
At close: May 31, 2026
ASE:JPHM Income Statement
Financials in millions JOD. Fiscal year is January - December.
Millions JOD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 24.46 | 16.86 | 14.58 | 16.96 | 15.83 | 14.92 | |
Revenue Growth (YoY) | 63.74% | 15.65% | -14.03% | 7.16% | 6.12% | 49.49% |
Cost of Revenue | 12.06 | 9.78 | 11.01 | 10.11 | 10.79 | 9.93 |
Gross Profit | 12.4 | 7.08 | 3.57 | 6.86 | 5.04 | 4.99 |
Selling, General & Admin | 5.89 | 5.76 | 4.99 | 5.44 | 7.21 | 7.95 |
Research & Development | 0.34 | 0.36 | 0.48 | 0.47 | 0.41 | - |
Amortization of Goodwill & Intangibles | 0.06 | 0.06 | 0.04 | 0.04 | 0.03 | 0.04 |
Other Operating Expenses | 0.61 | 0.61 | 0.06 | 0.42 | - | - |
Operating Expenses | 6.9 | 6.79 | 5.58 | 7.73 | 7.65 | 7.98 |
Operating Income | 5.5 | 0.29 | -2.01 | -0.88 | -2.61 | -2.99 |
Interest Expense | -0.3 | -0.39 | -0.65 | -1.32 | -0.93 | -1.48 |
Earnings From Equity Investments | 0.84 | 1.51 | 0.23 | 1.26 | -0.11 | 0.15 |
Currency Exchange Gain (Loss) | - | - | -0.08 | -0.06 | -0 | -0.02 |
Other Non Operating Income (Expenses) | -0.12 | -0.34 | -0.13 | 0.18 | 0.01 | 0.01 |
EBT Excluding Unusual Items | 5.92 | 1.06 | -2.63 | -0.83 | -3.64 | -4.33 |
Gain (Loss) on Sale of Assets | - | - | - | -0.03 | - | 0.02 |
Asset Writedown | -0.06 | -0.08 | -0.07 | -0.07 | -0.07 | -0.09 |
Legal Settlements | - | - | - | - | 2.83 | -5.67 |
Other Unusual Items | - | - | - | - | 1.03 | 0.49 |
Pretax Income | 5.87 | 0.98 | -2.71 | -0.92 | 0.15 | -9.58 |
Income Tax Expense | 1 | 0.34 | 0.14 | -1.14 | 0.06 | 2.1 |
Earnings From Continuing Operations | 4.87 | 0.64 | -2.85 | 0.22 | 0.09 | -11.68 |
Minority Interest in Earnings | -0 | 0.01 | -0 | 0 | 0.03 | 0.05 |
Net Income | 4.86 | 0.65 | -2.86 | 0.22 | 0.12 | -11.64 |
Net Income to Common | 4.86 | 0.65 | -2.86 | 0.22 | 0.12 | -11.64 |
Net Income Growth | - | - | - | 79.58% | - | - |
Shares Outstanding (Basic) | 34 | 34 | 34 | 69 | 69 | 25 |
Shares Outstanding (Diluted) | 34 | 34 | 34 | 69 | 69 | 25 |
Shares Change (YoY) | -51.69% | - | -50.83% | - | 170.77% | - |
EPS (Basic) | 0.14 | 0.02 | -0.08 | 0.00 | 0.00 | -0.46 |
EPS (Diluted) | 0.14 | 0.02 | -0.08 | 0.00 | 0.00 | -0.46 |
EPS Growth | - | - | - | 79.56% | - | - |
Free Cash Flow | 4.26 | 0.98 | 0.4 | -6.59 | -0.32 | -9.66 |
Free Cash Flow Per Share | 0.13 | 0.03 | 0.01 | -0.10 | -0.01 | -0.38 |
Gross Margin | 50.68% | 42.00% | 24.51% | 40.42% | 31.85% | 33.45% |
Operating Margin | 22.48% | 1.71% | -13.77% | -5.17% | -16.48% | -20.07% |
Profit Margin | 19.88% | 3.86% | -19.59% | 1.29% | 0.77% | -78.02% |
Free Cash Flow Margin | 17.43% | 5.82% | 2.75% | -38.88% | -2.02% | -64.79% |
EBITDA | 6.13 | 1.08 | -1.41 | -0.37 | -2.19 | -2.56 |
EBITDA Margin | 25.05% | 6.41% | -9.66% | -2.19% | -13.82% | -17.13% |
D&A For EBITDA | 0.63 | 0.79 | 0.6 | 0.51 | 0.42 | 0.44 |
EBIT | 5.5 | 0.29 | -2.01 | -0.88 | -2.61 | -2.99 |
EBIT Margin | 22.48% | 1.71% | -13.77% | -5.17% | -16.47% | -20.07% |
Effective Tax Rate | 17.05% | 34.57% | - | - | 37.93% | - |
Advertising Expenses | - | 0.24 | 0.1 | 0.14 | 0.32 | 0.58 |